So Honored!

Please Scroll Down for Blog Posts

Books Written by FiveSibesMom

Come Visit Our Facebook Page!

Buy Books Here! A portion donated to Canine Epilepsy Research and Siberian Husky Rescues!

This Site (Articles, Photos & Videos) is Copyright Protected. Permission to Reprint Required.

Protected by Copyscape Web Plagiarism Scanner

FiveSibes Star in Singer Nancy Simmonds' Music Video!

#FiveSibes #LiveGibStrong #LiveGibStrongForever

Scroll Down for Current Blog Posts!

All Blog Posts, Photos & Videos Are:

Protected by Copyscape DMCA Takedown Notice Violation Search

Feel free to SHARE our blog link.

Shop PetSmart with FiveSibes!


Like our blog?

Like our blog?
Please Vote for Us! Thank You!

Tuesday, November 25, 2014

N.C. State U/College of Veterinary Medicine Recruiting Epi-Dogs on Keppra XR for Study ~and~ Our #LiveGibStrong Epi-Tip #25

Click on photo to enlarge. You MAY share this image.

 Recruiting Epi-Dogs for Canine Keppra Extended Release Pharmacokinetic Study

Recruitment is open for dogs with epilepsy that are being treated with Keppra XR (levetiracetam extended release)) and Phenobarbital (group I) Keppra XR and Zonisamide (Zonegran) (group II) , or Keppra XR alone (group III) for a Pharmacokinetic study. This study is being conducted at North Carolina State University-College of Veterinary Medicine, under the direction of Dr. Karen Muñana, DVM, DACVIM (Neurology).

If your dog has been diagnosed with epilepsy, and is receiving the drugs listed above in any of the 3 groups listed, we are interested in sampling your pet to determine how Keppra XR interacts with the other anticonvulsants through sequential blood sampling in a one-day study. All blood levels will be provided to the owners at no-charge. If you are interested in more information regarding this project, or to see if your pet qualifies, please CONTACT Julie Nettifee or 919-513-6812. 
If unable to travel to NC State, arrangements can be made in most cases to have sampling performed by your referring veterinarian.

* * * * *

No comments:

Post a Comment